A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the FirstLine Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)
Sponsor: Merck Sharp & Dohme Corp.
Participating sites:
- AZ Maria Middelares, Gent
- Imelda Ziekenhuis, Bonheiden
- Grand Hôpital de Charleroi, Charleroi
- Hôpital de Libramont, Libramont
- UZ Leuven, Leuven
- UZ Gent, Gent
- Jessa Ziekenhuis, Hasselt
- CHU de Liège, site Sart Tilman, Liège
- UZ Antwerpen, Antwerpen
- CHU UCL St-Luc, Bruxelles
